159P - Early radiological response (ERR) as predictor of overall survival in non small cell lung cancer (NSCLC) patients with EGFR mutations

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Staging Procedures (clinical staging)
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter Carmen Salvador Coloma
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors C. Salvador Coloma1, O.M. Niño1, J. Gomez Codina1, C. Escoin Pérez1, S. Palanca2, D. Akhoundova Sanoyan1, M. Melián1, J. Montalar1, O. Juan1
  • 1Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 2Biology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES



New cancer agents have been active in the treatment of advanced NSCLC with EGFR mutations. Currently, the response to chemotherapy is evaluated after the patient completes the 2nd course of treatment. The time for evaluation of TKI is not well-defined


EGFR mutation status was analyzed in 360 NSCLC patients' samples (January 2009 to November 2014). 55 patients (15%) were EGFR mutation positive and only 40 of them who were stage IIIB-IV and had received treatment with gefitinib, erlotinib or afatinib were included in this analysis. The principal aim was to correlate the ERR to TKI by CT with PFS and OS in advanced NSCLC patients with EGFR mutations


Patient characteristics in Table 1. The EGFR mutations were mainly exon 19 deletions (14 patients) and L858R point mutations (16 patients). 26 patients (65%) had ERR. 4 patients with partial response (PR) on early CT achieved a complete response (CR) in the evolution. The median follow-up was 21 months (m). The median PFS was 11 m for patients with ERR and 2.3 m for patients with stable disease (SD) and progressive disease (PD). The median OS for patients with ERR was 23.3 m and patients with SD and PD were 12 m. The overall log-rank test, when comparing the groups (ERR vs SD and PD) showed for PFS (p 


ERR could identify a subgroup of patients with activating EGFR mutation and poor prognosis in spite of the treatment with TKI. Further efforts are needed to improve the diagnosis and the treatment of this subgroup of patients

Clinical trial identification

Legal entity responsible for the study

Hospital La Fe




All authors have declared no conflicts of interest.